The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 11, 2021

Filed:

Dec. 13, 2019
Applicant:

Affimed Gmbh, Heidelberg, DE;

Inventors:

Michael Tesar, Heidelberg, DE;

Kristina Ellwanger, Heidelberg, DE;

Ivica Fucek, Heidelberg, DE;

Uwe Reusch, Heidelberg, DE;

Thorsten Ross, Heidelberg, DE;

Joachim Koch, Heidelberg, DE;

Erich Rajkovic, Heidelberg, DE;

Martin Treder, Heidelberg, DE;

Assignee:

Affimed GmbH, Heidelberg, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); C12P 21/08 (2006.01); A61K 39/395 (2006.01); A61K 39/40 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); C07K 1/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/283 (2013.01); A61P 35/00 (2018.01); C07K 16/2878 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/35 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01);
Abstract

The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (FcγRIIIA) expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.


Find Patent Forward Citations

Loading…